Evidence map›Paper›PMID 30311350›Full record

ArticleTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2019

A Retrospective Study on Erythropoiesis Stimulating Agent Dose Reducing Potential of an Anti-Platelet Activation Membrane Dialyzer in Hemodialysis Patients.

Takatoshi Kakuta, Mari Ishida, Hirotaka Komaba, Hajime Suzuki, Masafumi Fukagawa

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Takatoshi KakutaDivision of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7235-0726
Mari IshidaDivision of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University Hachioji Hospital, Hachioji, Tokyo, Japan.
Hirotaka KomabaDivision of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-1704-4507
Hajime SuzukiDivision of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
Masafumi FukagawaDivision of Nephrology, Endocrinology and Metabolism, Department of Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.

Funding

Toray Medical Co., Ltd
6 · The paper itself

Abstract

Our previous small-scale trial demonstrated an erythropoiesis stimulating agent (ESA)-sparing potential of the TORAYLIGHT NV (NV) dialyzer in hemodialysis patients with high interleukin-6 levels. We now retrospectively explored this ESA-sparing potential of the NV dialyzer in 122 and 129 prevalent dialysis patients who were on the NV and conventional polysulfone (PS) dialyzers, respectively, for 12 months. ESA resistance index (ERI) increased with the PS dialyzers whereas neither ERI nor ESA dose changed with the NV dialyzer. Analyses of baseline ERI or ESA dose-based subgroups revealed a decrease in ERI and ESA dose with the NV dialyzer in patients with a baseline ERI ≥12 IU·dL/week·kg·g Hb (P < 0.05) and in those with a baseline ESA dose >6000 IU/week (P < 0.001), respectively. Neither ERI nor ESA dose improved in the corresponding subgroups on the PS dialyzers. These findings suggest that NV dialyzer can improve ESA responsiveness in hemodialysis patients with advanced ESA resistance.

Indexed as

AdultAgedAged, 80 and overDose-Response Relationship, DrugHematinicsHumansInterleukin-6MaleMiddle AgedPlatelet ActivationPolymersRenal DialysisRetrospective StudiesSulfonesYoung AdultHematinicsInterleukin-6Polymerspolysulfone P 1700SulfonesAnti-platelet activation membraneErythropoiesis stimulating agent resistanceNV dialyzerPolysulfone membraneRenal anemia

Identifiers

PMID30311350
PMCPMC7379541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.